X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-28 | INBX | Viking Global Investors LP | 10% | P - Purchase | $19.35 | +511,627 | 7,150,826 | +8% | +$9,899,982 | |||||
2023-03-01 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale | $24.21 | -40,000 | 2,355,553 | -2% | -$968,231 | ||||||
2023-02-28 | INBX | Lappe Mark | CEO | S - Sale | $25.02 | -60 | 3,045,654 | 0% | -$1,501 | ||||||
| M | 2023-02-01 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale | $24.93 | -40,000 | 2,395,553 | -2% | -$997,210 | |||||
| M | 2023-01-23 | INBX | Lappe Mark | CEO | S - Sale | $25.42 | -26,000 | 3,045,714 | -1% | -$660,842 | |||||
2023-01-23 | INBX | Kayyem Jon Faiz | Dir | S - Sale | $25.26 | -9,500 | 3,274,301 | 0% | -$239,999 | ||||||
| DM | 2023-01-03 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale+OE | $23.72 | -40,000 | 2,435,553 | -2% | -$948,598 | |||||
2022-12-21 | INBX | Kayyem Jon Faiz | Dir | S - Sale | $27.02 | -9,500 | 3,283,801 | 0% | -$256,679 | ||||||
2022-12-19 | INBX | Lappe Mark | CEO | S - Sale | $25.56 | -26,000 | 3,071,714 | -1% | -$664,443 | ||||||
2022-12-06 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale | $27.22 | -40,000 | 2,475,553 | -2% | -$1,088,683 | ||||||
2022-11-21 | INBX | Kayyem Jon Faiz | Dir | S - Sale | $29.89 | -9,500 | 3,293,301 | 0% | -$283,972 | ||||||
2022-11-17 | INBX | Lappe Mark | CEO | S - Sale | $27.88 | -26,000 | 3,097,714 | -1% | -$724,910 | ||||||
2022-11-01 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale | $33.51 | -40,000 | 2,515,553 | -2% | -$1,340,387 | ||||||
2022-10-21 | INBX | Kayyem Jon Faiz | Dir | S - Sale | $30.13 | -9,500 | 3,302,801 | 0% | -$286,232 | ||||||
2022-10-17 | INBX | Lappe Mark | CEO | S - Sale | $29.59 | -26,000 | 3,123,714 | -1% | -$769,443 | ||||||
2022-10-07 | INBX | Viking Global Investors LP | 10% | P - Purchase | $30.00 | +1,333,333 | 4,211,892 | +46% | +$39,999,857 | ||||||
2022-10-04 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale | $27.82 | -40,000 | 2,555,553 | -2% | -$1,112,813 | ||||||
2022-09-06 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale | $14.91 | -40,000 | 2,595,553 | -2% | -$596,274 | ||||||
| M | 2022-08-02 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale | $18.00 | -40,000 | 2,635,553 | -1% | -$719,835 | |||||
2022-07-07 | INBX | Eckelman Brendan P. | Chief Scientific Officer | S - Sale | $17.17 | -40,000 | 2,675,553 | -1% | -$686,800 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |